Paratek Pharmaceuticals Receives a Buy from H.C. Wainwright

By Austin Angelo

H.C. Wainwright analyst Ed Arce reiterated a Buy rating on Paratek Pharmaceuticals (NASDAQ: PRTK) today and set a price target of $43. The company’s shares closed yesterday at $24.95, close to its 52-week high of $26.10.

According to TipRanks.com, Arce is a 5-star analyst with an average return of 27.4% and a 50.6% success rate. Arce covers the Healthcare sector, focusing on stocks such as Neptune Technologies & Bioresources Inc, Aviragen Therapeutics Inc, and Sucampo Pharmaceuticals.

Currently, the analyst consensus on Paratek Pharmaceuticals is Strong Buy and the average price target is $43.33, representing a 73.7% upside.

In a report released yesterday, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $50 price target.

The company has a one year high of $26.10 and a one year low of $9.80. Currently, Paratek Pharmaceuticals has an average volume of 619.1K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Paratek Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon its expertise in novel tetracycline chemistry. Its products include Omadacycline and Sarecycline. The company was founded in February 2001 and is headquartered in Boston, MA.